Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Arcus Biosciences, Inc.
NYSE:RCUSHealthcare · Biotechnology
-4.24%$18.54
AH Close$18.54+0.00%vs close
AH Close$18.54+0.00%vs close
Mkt Cap$2.36B
Float88.69M
O/S127.33M
Inst Own71.7%
SI14.8%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$247M
Net Income-$353M
Total Assets$1.14B
Free Cash Flow-$484M
Debt & Equity
Debt 15%
Equity 85%
Total Debt$112M
Total Equity$631M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in RCUS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$1.14B
Liabilities$508M
Accounts Receivable$16M
Accounts Payable$42M
Inventory$0
PP&E (Net)$40M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $247M | $258M | $117M | $112M | $383M | $78M | $15M | $8.35M | $1.41M | $0 |
| YoY Growth | -4.3% | 120.5% | 4.5% | -70.8% | 391.0% | 420.0% | 79.6% | 491.2% | - | - |
| Cost of Revenue | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.31M |
| Gross Profit | $237M | $258M | $117M | $112M | $383M | $78M | $15M | $8.35M | $1.41M | -$1.31M |
| Gross Margin | 96.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | - |
| Research and Development | $523M | $448M | $340M | $288M | $257M | $159M | $78.48M | $49.65M | $47.22M | $14.25M |
| Selling, General, and Administrative | $110M | $120M | $117M | $104M | $72M | $43M | $25.23M | $13.57M | $7.64M | $3.94M |
| Other | -$10M | $20M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.31M |
| Total Operating Expenses | $623M | $588M | $457M | $392M | $329M | $202M | $103.71M | $63.21M | $54.85M | $16.87M |
| Operating Income (EBIT) | -$386M | -$330M | -$340M | -$280M | $54M | -$124M | -$88.71M | -$54.86M | -$53.44M | -$18.18M |
| Operating Margin | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% | -159.0% | -591.4% | -656.8% | -3782.1% | - |
| Interest Expense | $8M | $4M | $2M | $2M | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $41M | $52M | $41M | $16M | $1M | $1M | $5.2M | $4.92M | $775K | $212K |
| Other Income (Expense) | $33M | $47M | $39M | $14M | $1M | $1M | $4M | $5.26M | $359K | $212K |
| Income Before Tax (EBT) | -$353M | -$283M | -$301M | -$266M | $55M | -$123M | -$84.71M | -$49.59M | -$53.08M | -$17.97M |
| Income Tax Expense | $0 | $1M | $6M | $1M | $2M | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$353M | -$283M | -$307M | -$267M | $53M | -$123M | -$84.71M | -$49.59M | -$53.08M | -$17.97M |
| Net Income Margin | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | - |
| Supplementary Data | ||||||||||
| EPS | -3.29 | -3.14 | -4.15 | -3.71 | 0.76 | -2.24 | -1.93 | -1.43 | -2.16 | -0.73 |
| Diluted EPS | -3.29 | -3.14 | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 | -1.43 | -2.16 | -0.73 |
| Weighted Average OS | 107.40M | 90.10M | 74.00M | 72.00M | 69.35M | 54.79M | 43.83M | 34.62M | 24.55M | 24.55M |
| EBITDA | -$335M | -$269M | -$291M | -$258M | $59M | -$120M | -$81.13M | -$51.2M | -$50.83M | -$16.87M |
| EBITDA Margin | -135.6% | -104.3% | -248.7% | -230.4% | 15.4% | -153.8% | -540.9% | -612.9% | -3597.2% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Assets | ||||||||||
| Current Assets | ||||||||||
| Cash and Cash Equivalents | $222M | $150M | $127M | $206M | $147.91M | $173.41M | $57.94M | $71.06M | $98.43M | $65.16M |
| Short-Term Investments | $759M | $828M | $632M | $803M | $351.39M | $555.23M | $130.33M | $185.48M | $77.28M | $33.74M |
| Cash and Short-Term Investments | $981M | $978M | $759M | $1.01B | $499.31M | $728.65M | $188.27M | $256.54M | $175.7M | $98.9M |
| Accounts Receivable | $16M | $25M | $42M | $43M | $746.82M | $1.7M | $132K | $83K | $25K | $405K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $10M | $13M | $30M | $14M | $14.72M | $4.47M | $251K | $0 | $0 | $0 |
| Total Current Assets | $1.01B | $1.02B | $831M | $1.07B | $1.26B | $735.82M | $192.71M | $258.95M | $176.87M | $99.69M |
| Long-Term Assets | ||||||||||
| Property, Plant & Equipment Net | $40M | $47M | $51M | $135M | $137.42M | $23.59M | $9.33M | $11.11M | $11.23M | $8.61M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $29M | $14M | $107M | $134M | $185M | $6.64M | $0 | $4.38M | $682K | $1M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $63M | $73M | $106M | $10M | $7.73M | $6.25M | $1.07M | $487K | $1.71M | $403K |
| Total Long-Term Assets | $132M | $134M | $264M | $279M | $330.15M | $36.48M | $10.4M | $15.98M | $13.62M | $10.01M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B | $772.29M | $203.11M | $274.93M | $190.49M | $109.7M |
| Liabilities | ||||||||||
| Current Liabilities | ||||||||||
| Accounts Payable | $42M | $18M | $17M | $20M | $10.26M | $15.68M | $4.7M | $3.1M | $3.82M | $3.87M |
| Short-Term Debt | $0 | $0 | $0 | $3M | $5.1M | $2.87M | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $1M | $0 | $0 | $1.81M | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $35M | $85M | $91M | $97M | $102M | $74.57M | $7M | $6.25M | $5M | $0 |
| Other Current Liabilities | $18M | $14M | $39M | $48M | $30.26M | $19.92M | $6.43M | $1.56M | $769K | $682K |
| Total Current Liabilities | $231M | $226M | $184M | $193M | $166.08M | $121.67M | $22.71M | $16.93M | $12.73M | $5.55M |
| Long-Term Liabilities | ||||||||||
| Long-Term Debt | $99M | $48M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $43M | $234M | $307M | $355M | $462.22M | $122.83M | $12.02M | $16.98M | $18.59M | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $135M | $157M | $142M | $23M | $5.26M | $10.25M | $4.54M | $6.06M | $5.3M | $4.7M |
| Total Long-Term Liabilities | $277M | $439M | $449M | $495M | $584.36M | $148.32M | $16.56M | $23.05M | $23.89M | $4.7M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $508M | $665M | $633M | $688M | $750.45M | $269.99M | $39.27M | $39.98M | $36.62M | $10.24M |
| Stockholders' Equity | ||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $226.2M | $119.45M |
| Common Stock | $2.12B | $1.62B | $1.31B | $1.21B | $7K | $6K | $4K | $4K | $3K | $1K |
| Retained Earnings | -$1.49B | -$1.13B | -$849M | -$542M | -$275.35M | -$328.18M | -$205.33M | -$122.83M | -$73.23M | -$20.15M |
| Comprehensive Income & Other | $0 | $0 | $0 | -$7M | -$1.26M | $44K | $64K | -$107K | -$42K | -$26K |
| Other Stockholders' Equity | $0 | $0 | $0 | -$7M | $1.12B | $830.48M | $369.16M | $357.77M | $227.1M | $119.61M |
| Total Equity | $631M | $485M | $462M | $657M | $841.45M | $502.3M | $163.84M | $234.94M | $153.87M | $99.46M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B | $772.29M | $203.11M | $274.93M | $190.49M | $109.7M |
| Supplementary Data | ||||||||||
| Total Debt | $112M | $60M | $11M | $120M | $121.99M | $18.11M | $0 | $0 | $0 | $0 |
| Net Debt | -$110M | -$90M | -$116M | -$86M | -$25.93M | -$155.31M | -$57.94M | -$71.06M | -$98.43M | -$65.16M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Operating Activities | ||||||||||
| Net Income | -$353M | -$283M | -$307M | -$267M | $52.83M | -$122.86M | -$84.71M | -$49.59M | -$53.08M | -$17.97M |
| Depreciation & Amortization | $10M | $10M | $8M | $6M | $4M | $3M | $3.58M | $3.66M | $2.61M | $1.31M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2.1M | $416K | -$90K |
| Stock-Based Compensation | $60M | $76M | $73M | $65M | $55M | $22M | $8.98M | $3.87M | $495K | $90K |
| Changes in Working Capital: | ||||||||||
| Accounts Receivable | $9M | $28M | $15M | $704M | -$17.05M | -$917K | -$49K | -$58K | $380K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $21.32M | $0 | $0 | $0 | $0 |
| Accounts Payable | $24M | $3M | -$1M | $8M | -$4.77M | $9.27M | $1.73M | -$69K | -$267K | $3.57M |
| Other Working Capital | -$227M | -$9M | -$85M | -$89M | -$353.8M | $178.38M | -$1.55M | $1.46M | $24.48M | $53K |
| Total Working Capital Change | -$194M | $22M | -$71M | $623M | -$375.62M | $208.06M | $125K | $1.33M | $24.6M | $3.62M |
| Other Non-Cash Items | -$5M | $5M | -$9M | $11M | $7.62M | $970K | -$1.44M | -$177K | -$98K | $90K |
| Net Cash from Operating | -$482M | -$170M | -$306M | $438M | -$256.17M | $111.17M | -$73.46M | -$43M | -$25.06M | -$12.94M |
| Investing Activities | ||||||||||
| Capital Expenditures | -$2M | -$6M | -$24M | -$6M | -$26.08M | -$3.06M | -$1.93M | -$3.74M | -$5.51M | -$4.1M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $431M | $0 | $0 | $0 | -$1M |
| Purchases of Investments | -$1.08B | -$1.04B | -$788M | -$1.24B | -$718.87M | -$739.66M | -$247.75M | -$261.55M | -$96.83M | -$33.76M |
| Sales of Investments | $1.14B | $965M | $1.01B | $837M | $741.08M | $308.35M | $308.89M | $151.85M | $53.27M | $1M |
| Other Investing Activities | $0 | $0 | $0 | -$3M | $0 | -$431M | $0 | $0 | $0 | -$1M |
| Net Cash from Investing | $66M | -$84M | $194M | -$413M | -$3.87M | -$434.37M | $59.21M | -$113.44M | -$49.07M | -$38.86M |
| Financing Activities | ||||||||||
| Debt Repaid | -$49M | -$47M | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $439M | $228M | $25M | $23M | $232.35M | $434M | $0 | $125.11M | $107.4M | $70.1M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | -$6K | -$54K | -$94K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $2M | $8M | $10M | $0 | $4.67M | $1.22M | $3.96M | $519K | $283K |
| Net Cash from Financing | $488M | $277M | $33M | $33M | $237.34M | $438.68M | $1.12M | $129.07M | $107.4M | $70.1M |
| Forex Effect | $0 | $0 | $0 | $0 | -$2.8M | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $72M | $23M | -$79M | $58M | -$25.5M | $115.48M | -$13.13M | -$27.36M | $33.27M | $18.3M |
| Supplementary Data | ||||||||||
| Operating Cash Flow | -$482M | -$170M | -$306M | $438M | -$256.17M | $111.17M | -$73.46M | -$43M | -$25.06M | -$12.94M |
| Capital Expenditure | -$2M | -$6M | -$24M | -$6M | -$26.08M | -$3.06M | -$1.93M | -$3.74M | -$5.51M | -$4.1M |
| Free Cash Flow | -$484M | -$176M | -$330M | $432M | -$282.25M | $108.11M | -$75.39M | -$46.74M | -$30.57M | -$17.04M |
| Cash at Beginning | $153M | $130M | $209M | $151M | $173.41M | $58.14M | $71.27M | $98.43M | $65.16M | $46.87M |
| Cash at End | $225M | $153M | $130M | $209M | $147.91M | $173.62M | $58.14M | $71.06M | $98.43M | $65.16M |